Crohn's Disease News and Research RSS Feed - Crohn's Disease News and Research

Crohn’s disease is a chronic inflammatory disease of the bowel affecting at least 115,000 people in the UK. The condition usually develops in teenagers and young adults, but can be diagnosed at any age and is equally common in men and women.

The condition can affect any part of the digestive tract between the mouth and the anus, although inflammation in the last section of the small bowel (ileum) or the first part of the large bowel (colon) is most common.

Crohn's disease is a ‘relapsing and remitting’ condition characterized by symptom-free periods followed by episodes of “flare-ups,” during which symptoms such as diarrhoea, abdominal pain, fever and fatigue may become particularly bothersome.

Long term, severe inflammation can damage sections of the digestive system, resulting in additional complications, such as a tear in the wall of the anus (fissure), narrowing of the intestine (stricture) or the formation of an abnormal connection between the bowel and another body part such as the bladder, vagina or skin (fistula). Such problems usually require surgical treatment to correct. Crohn's disease also increases the risk of developing bowel cancer.

The exact cause of Crohn's disease is not clear but experts believe a combination of factors may be at work including genetics, immune responses to certain bacteria or viruses and lifestyle factors such as diet or smoking status.
Cell Science Systems launches new blood test profile for GI disorders

Cell Science Systems launches new blood test profile for GI disorders

Distinguishing the cause of gut disorders can be complicated. Therefore, Cell Science Systems, Corp. today announced the launch of a new test to help clinicians reach a diagnosis; and, suggest dietary strategies to improve whatever gut malady a person may have. [More]
AbbVie receives HUMIRA orphan drug designation from FDA for treatment of non-infectious uveitis

AbbVie receives HUMIRA orphan drug designation from FDA for treatment of non-infectious uveitis

AbbVie announced today that the U.S. Food and Drug Administration has granted HUMIRA orphan drug designation for the treatment of non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior uveitis, a group of rare but serious inflammatory diseases of the eye. [More]
FDA approves Takeda's Entyvio for severe active ulcerative colitis and Crohn's disease

FDA approves Takeda's Entyvio for severe active ulcerative colitis and Crohn's disease

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., has announced that the United States (U.S.) Food and Drug Administration (FDA) simultaneously approved a new biologic therapy, Entyvio™ (vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD). [More]
Ferring launches new interactive website Guts4life for people with IBD

Ferring launches new interactive website Guts4life for people with IBD

Ferring Pharmaceuticals marks World IBD Day (May 19th) with the launch of Guts4life (www.guts4life.com), a new interactive website with information, support and inspiration for people concerned with Crohn's disease and ulcerative colitis, conditions known as inflammatory bowel diseases (IBD). [More]
Study shows technology improves transition into adulthood for adolescents with chronic disease

Study shows technology improves transition into adulthood for adolescents with chronic disease

Adolescents with chronic diseases (ACD), such as cystic fibrosis, gastrointestinal disorders (including Crohn's disease) and Type 1 diabetes, often find the transition of managing their health care needs into adulthood to be challenging. [More]
Study finds increased risk of hospitalization for heart failure in IBD patients

Study finds increased risk of hospitalization for heart failure in IBD patients

Heart failure hospitalisation more than doubles during inflammatory bowel disease (IBD) flares, according to a study of more than 5 million Danish people. The research was presented today at the Heart Failure Congress 2014, held 17-20 May, in Athens, Greece. [More]
Autoimmune epilepsy diagnostics: an interview with Dr. Joseph J. Higgins, Medical Director, Neurology, Athena Diagnostics, a business of Quest Diagnostics

Autoimmune epilepsy diagnostics: an interview with Dr. Joseph J. Higgins, Medical Director, Neurology, Athena Diagnostics, a business of Quest Diagnostics

Epilepsy is a group of neurological disorders often characterized by seizures and cognitive impairment due to electrical disturbances in the brain. [More]
Melbourne researchers find link between necroptosis and inflammatory disease

Melbourne researchers find link between necroptosis and inflammatory disease

A team of Melbourne researchers has shown a recently discovered type of cell death called necroptosis could be the underlying cause of inflammatory disease. [More]
Salix Pharmaceuticals' total net product revenue increases 90% to $384.4 million in Q1 2014

Salix Pharmaceuticals' total net product revenue increases 90% to $384.4 million in Q1 2014

Salix Pharmaceuticals, Ltd. today announced financial and operating results for the first quarter ended March 31, 2014, and other business updates. [More]
Psychologists and physicians help address barriers to improved primary health care

Psychologists and physicians help address barriers to improved primary health care

Primary care teams that include both psychologists and physicians would help address known barriers to improved primary health care, including missed diagnoses, a lack of attention to behavioral factors and limited patient access to needed care, according to health care experts writing in a special issue of American Psychologist, the flagship journal of the American Psychological Association. [More]
Eli and Edythe Broad Foundation gift $4 million to support UCLA research

Eli and Edythe Broad Foundation gift $4 million to support UCLA research

Two new gifts from The Eli and Edythe Broad Foundation to UCLA totaling $4 million will fund research in stem cell science and digestive diseases and support the recruitment of key faculty at two renowned research centers. [More]
Power of GWAS to detect human disease can be increased using statistical testing

Power of GWAS to detect human disease can be increased using statistical testing

The power of genome-wide association studies (GWAS) to detect genetic influences on human disease can be substantially increased using a statistical testing framework reported in the May issue of the journal GENETICS. [More]
UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

UCB announced today results from the PRECiSE 3 7-year open label extension clinical trial of Cimzia (certolizumab pegol), the longest continuous trial of an anti-TNF therapy evaluating long-term safety in Crohn's disease. [More]
Olympus launches next-generation ENDOCAPSULE 10 System for capsule endoscopy procedures

Olympus launches next-generation ENDOCAPSULE 10 System for capsule endoscopy procedures

Olympus, a precision technology leader in designing and delivering innovative solutions in Medical and Surgical Products, among other core businesses, announced today the commercial availability of its 510(k) cleared, next-generation ENDOCAPSULE 10 System for small bowel capsule endoscopy procedures. [More]
GPs need enhanced training to help manage patients with psoriasis, say experts

GPs need enhanced training to help manage patients with psoriasis, say experts

GPs need enhanced training to help them to manage patients with the complex, long term condition psoriasis which affects 1.8 million people in the UK, experts from The University of Manchester argue. [More]
Ruthigen files IND Application to FDA for lead drug candidate RUT58-60

Ruthigen files IND Application to FDA for lead drug candidate RUT58-60

Ruthigen, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics designed to prevent and treat infection in invasive applications, today announced that the Company has submitted an Investigational New Drug (IND) Application to the U.S. Food and Drug Administration for its lead drug candidate RUT58-60. [More]
Studies identify 2 genes highly associated with IBD

Studies identify 2 genes highly associated with IBD

Inflammatory Bowel Disease (IBD), a group of chronic inflammatory disorders of the intestine that result in painful and debilitating complications, affects over 1.4 million people in the U.S., and while there are treatments to reduce inflammation for patients, there is no cure. [More]
AARDA launches autoimmune curriculum for teachers of grades three through eight

AARDA launches autoimmune curriculum for teachers of grades three through eight

Furthering its mission of educating all Americans about autoimmunity and autoimmune disease (AD), the American Autoimmune Related Diseases Association, Inc. (AARDA) has launched the first-of-its kind autoimmune curriculum for teachers of grades three through eight. [More]
Study sheds light on factors that lead to development of rare condition affecting inner ear

Study sheds light on factors that lead to development of rare condition affecting inner ear

A new study has shed light on the factors likely to lead to the development of a rare condition affecting the inner ear. [More]
New insights provide novel therapeutic approach against cancer

New insights provide novel therapeutic approach against cancer

A major discovery that brings a new drug target to the increasingly exciting landscape of cancer immunotherapy was published yesterday by researchers from La Jolla Institute for Allergy and Immunology and their collaborators from other institutes. [More]